For drugmakers, distributors and hospital pharmacies, the India cancer medicine price revision 2026 is a margin story. The National Pharmaceutical Pricing Authority, or NPPA, has published revised maximum retail prices for 543 anti-cancer brands and pack sizes, with the new rates effective 9 November 2026, according to press reports. The list follows the government’s 17 October decision to cap trade margins at 30% on 137 non-scheduled anti-cancer medicines. This article looks at how the revision may affect different parts of the pharmaceutical supply chain, what the data show and where the evidence is incomplete.
Key takeaways from the India cancer medicine price revision 2026 for the industry
- 543 brands and pack sizes have revised MRPs effective 9 November 2026, based on company submissions up to 27 October.
- The cap limits trade margin to 30% of MRP excluding GST, equal to about 42.86% markup on the stockist price.
- Reported cuts reach 93.3% for a palbociclib brand, and several generics fall by more than 60%.
- Some originator brands, including bevacizumab and pembrolizumab, are reported unchanged, while biosimilars fell.
- MRPs are self-reported by companies, and the NPPA says it will update the list as submissions arrive.
How the India cancer medicine price revision 2026 reaches the supply chain
A medicine passes from manufacturer to stockist, then to retailer or hospital. Each takes a margin, and the MRP printed on the pack is the ceiling the patient pays. By capping the trade margin at 30% of MRP, the policy removes the room to print an MRP far above the price the trade pays. Companies therefore re-set MRPs, and the NPPA compiles them. Reports say manufacturers must pass the changes through the chain and state drug controllers are expected to monitor compliance. The authority is described at the NPPA website.
Reported examples in the India cancer medicine price revision 2026
Press accounts give examples. RPG Life Sciences’ Anarzole (anastrozole, ten tablets) goes from Rs 695.76 to Rs 73. Dr Reddy’s Azacytin (azacitidine) goes from Rs 6,337 to Rs 1,495.04. Abbott’s Bevacizab (bevacizumab, 4 ml) goes from Rs 21,767.70 to Rs 5,930.13. Dasanat 20 (dasatinib) goes from Rs 2,812.50 to Rs 1,085.93. By our own calculation, those cuts are about 89.5%, 76.4%, 72.8% and 61.4%. One report says the sharpest cut was for RPG’s Palbopro (palbociclib), from Rs 40,421.33 to Rs 2,720, or 93.3%, which exceeded the government’s earlier indication of up to 70%. We have not checked these against the official schedule.
Winners and losers in the India cancer medicine price revision 2026
Patients and payers who paid inflated MRPs stand to benefit most. Within the industry, companies that relied on large trade margins on generics and biosimilars face the biggest adjustment. Originator brands whose prices stayed unchanged, as one report indicates, face less direct pressure. Distributors and retailers may see lower absolute margins because 30% of a lower MRP is a smaller amount. We cannot quantify the revenue effect on any company, and none has disclosed one in the coverage we reviewed.
Criticisms and gaps in the India cancer medicine price revision 2026
A drug-access network quoted in one report says free volumes given under patient assistance programmes were left out of the calculation, which blunted cuts on patented drugs, and that company-reported MRPs are not verified. An oncologist quoted in the same report suggests unchanged originator prices may reflect margins that were already reasonable. These are opinions, and the NPPA has not, in the material we reviewed, answered them. Verification of company-submitted data is a central open question for the policy.
Questions industry readers should ask after the India cancer medicine price revision 2026
How much stock with old MRPs remains in the channel, and will it be relabelled or sold through? Will hospitals that buy directly from manufacturers renegotiate prices? Will companies shift volumes toward brands outside the cap? Will any withdraw low-margin pack sizes? What happens to trade rebates and discounts that were built on the old MRPs? How quickly will the NPPA update its list? The coverage does not answer these, and we do not predict outcomes.
Cancer drug market data from Acumen Research and Consulting
Acumen Research and Consulting’s Cancer Therapeutics Market report values the global market at USD 193.7 billion in 2024 and projects USD 381.5 billion by 2033, a CAGR of 7.9% for 2025 to 2033. It gives North America about USD 71.7 billion in 2024, which by our own calculation is roughly 37% of the total, and Asia Pacific as the fastest-growing region at more than 8.8%. The page shows a last-updated date of 2019 that conflicts with its 2024 base year, so the figures are estimates. They are global and tell us nothing about Indian price changes. More in our industry insights.
Timeline of the India cancer medicine price revision 2026
- 2019: earlier margin cap on 42 anti-cancer drugs.
- 17 October 2026: decision on 137 non-scheduled anti-cancer medicines.
- 28 October 2026: 543-brand list reported.
- 9 November 2026: new MRPs take effect.
General background: how drug price control works in India
India controls medicine prices through the Drugs (Prices Control) Order, 2013. Scheduled medicines have ceiling prices set by the NPPA, while non-scheduled medicines can rise by a limited percentage annually. A trade margin cap is a different tool that targets the gap between trade price and MRP.
Our analysis of the India cancer medicine price revision 2026
In our assessment, the India cancer medicine price revision 2026 shifts the industry from an MRP-led model toward a price-to-trade model for the capped medicines. The scale of the reported cuts suggests margins were wide for many generics and biosimilars. The long-run effect depends on enforcement and on how companies respond. We do not give investment advice, and our calculations are illustrative.
What is not disclosed in the India cancer medicine price revision 2026
- Company-level financial impact.
- The official schedule in a form we could verify line by line.
- Verification and enforcement mechanisms.
Risks and caveats
Press-reported prices may contain errors and the list will be updated; the Department of Pharmaceuticals publishes related policy material at pharmaceuticals.gov.in. This article is news reporting and not investment advice.
What to watch next
- Updates to the NPPA list.
- Company statements and results commentary.
- Enforcement actions after 9 November.
FAQ
What is the margin cap?
A limit of 30% of MRP, excluding GST, on trade margins for 137 non-scheduled anti-cancer medicines.
When do the new MRPs apply?
From 9 November 2026.
Who reports the prices?
Companies submit them, and the NPPA compiles the list.
How we reported this: we relied on press reports of the NPPA list, the NPPA website and the Acumen Research and Consulting report cited above. Our calculations are labelled. Last updated 29 October 2026. This is news reporting and not advice.
